IGF2BP3 and acute myeloid leukemia: In the GSE37642 cohort, high expression of IGF2BP3 was a risk factor for AML (HR = 1.409, 95% CI = 1.185–1.675, P < 0.001), whereas HNRNPA2B1 was not (P = 0.754).